115 (Phospho)proteomics biomarkers for sunitinib response in RCC SUPPLEMENTARY TABLES AND FIGURES Supplementary Table 1. Clinicopathological data per individual patient 1: RCC = Renal Cell Carcinoma. 2: Gender: M = male, F = female. Age = at start sunitinib. 3: CC = clear cell, AC = adenocarcinoma, P = papillary, S = sarcomatoid, E = eosinophilic variant. 4: ASI trial81 = vaccination + CpG + GM-CSF, followed by CpG + Interferon. 5: Time in months between nephrectomy or metastasectomy and start sunitinib. 6: Best overall response according to RECIST 1.1. 7: Progression Free Survival in months. 8: Metastatic site: lymph nodes in cavernous sinus. 9: Metastatic site: liver. 10: Metastatic site: local recurrence in renal fossa. *: Measurements of tumor target lesions could not be performed, scan was performed elsewhere, radiology report states “decrease of metastatic lesions”. Patient is considered as sensitive to sunitinib. **: Metastatic lesion was resected after 2 months of therapy. Histological evaluation shows extensive necrosis of the metastatic lesion, therefore patient is considered as sensitive to sunitinib. NA: not applicable. Due to extensive necrotic tumor tissue, the tumor cell percentage could not be determined. Patient ID1 Gender, age2 Histology3 Lesion Prior immunotherapy4 Time to sunitinib5 Best response6 PFS7 Tumor cell % Protein input RCC1 M, 46 CC Primary ASI trial 7 PR 29.6 90 % 5 mg RCC2 M, 59 CC Primary ASI trial 4 PR 9.4 90 % 3 mg RCC3 M, 40 AC / P Primary Interferon 5 SD 10 80 % 3 mg RCC4 M, 60 AC / P Primary Interferon 36 SD 11.5 60 % 5 mg RCC5 M, 60 P Primary None 4 SD 3.2 40 % 5 mg RCC6 M, 79 CC / AC Primary None 63 PR 9.5 80 % 5 mg RCC7 F, 69 CC Primary None 2 SD 62.3 80 % 5 mg RCC8 F, 60 CC Primary None 1 SD/PR* 6 80 % 5 mg RCC9 M, 75 CC Primary None 10 SD 8 50 % 5 mg RCC10 M, 66 CC Metastatic8 None 4 SD 15.1 90 % 3 mg RCC11 F, 57 CC Primary None 2 PD 2.8 NA 5 mg RCC12 M, 64 CC Primary None 2 PD 2.4 90 % 3 mg RCC13 F, 64 CC Primary Interferon 26 SD 5 90 % 2 mg RCC14 F, 57 CC / P Primary ASI trial 5 PR 21.3 60 % 5 mg RCC15 F, 42 CC / E Primary None 10 PD 2.8 25% 5 mg RCC16 F, 62 CC Primary ASI trial 13 PR 5.8 50 % 3 mg RCC17 F, 47 CC Primary None 10 SD 14.4 NA 5 mg RCC18 M, 69 CC Primary None 6 SD 7 80 % 5 mg RCC19 M, 59 CC Primary None 4 PD 2.7 25 % 5 mg RCC20 F, 20 P Metastatic9 None 1 PD 1.5 60 % 5 mg RCC21 F, 67 CC Primary Interferon 15 SD 6 90 % 5 mg RCC22 M, 54 CC Primary ASI trial 24 PD 2.3 80 % 5 mg RCC23 M, 75 CC / S Primary None 1 PR 10.4 70 % 3 mg RCC24 M, 80 P Primary None 8 PD 2 70 % 5 mg RCC25 M, 80 P Primary None 16 PD 1.8 90 % 5 mg RCC26 F, 53 CC Metastatic10 None 1 SD NE** 90 % 5 mg 4
RkJQdWJsaXNoZXIy MTk4NDMw